ATOS
HEALTHCAREAtossa Therapeutics Inc
$5.80+0.22 (+3.94%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ATOS Today?
No stock-specific AI insight has been generated for ATOS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.76$19.35
$5.80
Fundamentals
Market Cap$50M
P/E Ratio—
EPS$-4.04
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume60K
Avg Volume (10D)—
Shares Outstanding8.6M
ATOS News
20 articles- Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal WomenYahoo Finance·May 6, 2026
- Atos and CNA strengthen long-term strategic partnership through new multi-year infrastructure services agreementYahoo Finance·May 5, 2026
- Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright SyndromeYahoo Finance·May 4, 2026
- Atos Advances AI-Ready Digital Transformation with Lumen Network as a ServiceYahoo Finance·Mar 31, 2026
- Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate UpdateYahoo Finance·Mar 25, 2026
- Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma ExecutivesYahoo Finance·Mar 19, 2026
- Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific ConferenceYahoo Finance·Mar 12, 2026
- Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 OutlookYahoo Finance·Feb 11, 2026
- We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth CarefullyYahoo Finance·Feb 9, 2026
- Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher ProgramYahoo Finance·Feb 5, 2026
- Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025Yahoo Finance·Jan 21, 2026
- Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular DystrophyYahoo Finance·Jan 16, 2026
- Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast CancerYahoo Finance·Jan 6, 2026
- Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy CategoryYahoo Finance·Dec 17, 2025
- Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer SymposiumYahoo Finance·Dec 15, 2025
- Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular DystrophyYahoo Finance·Dec 11, 2025
- Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-EndoxifenYahoo Finance·Dec 9, 2025
- Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer ContinuumYahoo Finance·Dec 4, 2025
- Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for GlioblastomaYahoo Finance·Dec 2, 2025
- Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific PresentationYahoo Finance·Nov 17, 2025
All 20 articles loaded
Price Data
Open$5.53
Previous Close$5.58
Day High$5.89
Day Low$5.49
52 Week High$19.35
52 Week Low$3.76
52-Week Range
$3.76$19.35
$5.80
Fundamentals
Market Cap$50M
P/E Ratio—
EPS$-4.04
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume60K
Avg Volume (10D)—
Shares Outstanding8.6M
About Atossa Therapeutics Inc
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—